Proteomics- and metabolomics-based neonatal diagnostics in assessing and managing the critically ill neonate.
The use of proteomic-based neonatal screening has been relatively limited until the present era and has focused primarily on the evaluation of newborns for inborn errors of metabolism. The future of proteomic-based screening seems to be much more encompassing, however. Tandem mass spectrometry and other related technologies are highly likely to be used in the evaluation of acute disease processes. Proteomics has the advantage over genomics of permitting a more direct look at an evolving disease process, because genomics primarily relates only the potential for a disease or abnormality to express itself. This article reviews the current uses of proteomics-based newborn evaluation and evaluates how this rapidly evolving area of medicine may be used to assess the fetus and the neonate in the near future.
Spitzer
Alan R
AR
The Center for Research and Education, Pediatrix Medical Group, Sunrise, FL 33323, USA. alan_spitzer@pediatrix.com
Chace
Donald
D
D016638:Critical Illness; D005315:Fetal Diseases / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000175:diagnosis* / Q000628:therapy*; D055432:Metabolomics / Q000379:methods*; D018743:Perinatal Care; D040901:Proteomics / Q000379:methods*